

John C Lieske

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2491782/publications.pdf>

Version: 2024-02-01

245
papers

10,792
citations

28274

55
h-index

43889

91
g-index

253
all docs

253
docs citations

253
times ranked

9404
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 36-46.	27.0	324
2	Current Issues in Measurement and Reporting of Urinary Albumin Excretion. <i>Clinical Chemistry</i> , 2009, 55, 24-38.	3.2	298
3	Kidney Stones and the Risk for Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 804-811.	4.5	296
4	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. <i>Kidney International</i> , 2013, 83, 749-756.	5.2	268
5	Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. <i>New England Journal of Medicine</i> , 2021, 384, 1216-1226.	27.0	265
6	Temporal Trends in Incidence of Kidney Stones Among Children: A 25-Year Population Based Study. <i>Journal of Urology</i> , 2012, 188, 247-252.	0.4	260
7	Single-Nephron Glomerular Filtration Rate in Healthy Adults. <i>New England Journal of Medicine</i> , 2017, 376, 2349-2357.	27.0	247
8	Hereditary causes of kidney stones and chronic kidney disease. <i>Pediatric Nephrology</i> , 2013, 28, 1923-1942.	1.7	213
9	Stone Composition as a Function of Age and Sex. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 2141-2146.	4.5	200
10	Kidney Stones Associate with Increased Risk for Myocardial Infarction. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1641-1644.	6.1	191
11	The ROKS Nomogram for Predicting a Second Symptomatic Stone Episode. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2878-2886.	6.1	190
12	Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2559-2570.	6.1	185
13	Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. <i>Critical Care Medicine</i> , 2017, 45, e23-e29.	0.9	179
14	Chronic Kidney Disease in Kidney Stone Formers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2069-2075.	4.5	163
15	Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. <i>Surgery for Obesity and Related Diseases</i> , 2005, 1, 481-485.	1.2	157
16	Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. <i>Surgery</i> , 2011, 149, 654-661.	1.9	152
17	Use of a probiotic to decrease enteric hyperoxaluria. <i>Kidney International</i> , 2005, 68, 1244-1249.	5.2	151
18	Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H1115-H1124.	3.2	142

#	ARTICLE	IF	CITATIONS
19	Relative Performance of the MDRD and CKD-EPI Equations for Estimating Glomerular Filtration Rate among Patients with Varied Clinical Presentations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1963-1972.	4.5	142
20	International Registry for Primary Hyperoxaluria. <i>American Journal of Nephrology</i> , 2005, 25, 290-296.	3.1	133
21	Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. <i>Kidney International</i> , 2010, 78, 1178-1185.	5.2	128
22	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. <i>Kidney International</i> , 2019, 95, 429-438.	5.2	123
23	Diabetes Mellitus and the Risk of Urinary Tract Stones: A Population-Based Case-Control Study. <i>American Journal of Kidney Diseases</i> , 2006, 48, 897-904.	1.9	122
24	Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. <i>Journal of Nephrology</i> , 2016, 29, 715-734.	2.0	122
25	Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. <i>Kidney International</i> , 2013, 83, 1169-1176.	5.2	119
26	Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells. <i>Kidney International</i> , 1997, 52, 1291-1301.	5.2	109
27	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. <i>Kidney International Reports</i> , 2018, 3, 56-64.	0.8	109
28	The Changing Incidence and Presentation of Urinary Stones Over 3 Decades. <i>Mayo Clinic Proceedings</i> , 2018, 93, 291-299.	3.0	107
29	Kidney stones are common after bariatric surgery. <i>Kidney International</i> , 2015, 87, 839-845.	5.2	106
30	Performance of Creatinine-Based GFR Estimating Equations in Solid-Organ Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2014, 63, 1007-1018.	1.9	103
31	Endocytosis of Calcium Oxalate Crystals and Proliferation of Renal Tubular Epithelial Cells in a Patient with Type 1 Primary Hyperoxaluria. <i>Journal of Urology</i> , 1992, 148, 1517-1519.	0.4	98
32	Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the Community. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1356-1365.	3.0	93
33	Risk Factors for CKD in Persons With Kidney Stones: A Case-Control Study in Olmsted County, Minnesota. <i>American Journal of Kidney Diseases</i> , 2010, 55, 61-68.	1.9	92
34	Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. <i>Kidney International</i> , 1995, 48, 501-509.	5.2	91
35	Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy: the Aging Kidney Anatomy study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 2034-2039.	0.7	90
36	Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. <i>Journal of Nephrology</i> , 2016, 29, 211-219.	2.0	86

#	ARTICLE	IF	CITATIONS
37	Risk of Acute Kidney Injury, Dialysis, and Mortality in Patients With Chronic Kidney Disease After Intravenous Contrast Material Exposure. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1046-1053.	3.0	81
38	Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 119-126.	4.5	81
39	Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. <i>American Journal of Kidney Diseases</i> , 2016, 68, 58-67.	1.9	78
40	Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression. <i>JAMA Internal Medicine</i> , 2019, 179, 542.	5.1	78
41	Update on Oxalate Crystal Disease. <i>Current Rheumatology Reports</i> , 2013, 15, 340.	4.7	74
42	Risk of ESRD and Mortality in Kidney and Bladder Stone Formers. <i>American Journal of Kidney Diseases</i> , 2018, 72, 790-797.	1.9	72
43	Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1175-1185.	0.7	71
44	Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes. <i>Mayo Clinic Proceedings</i> , 2019, 94, 202-210.	3.0	70
45	National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories. <i>Clinical Chemistry</i> , 2022, 68, 511-520.	3.2	70
46	Cell Biology of Pathologic Renal Calcification. <i>Journal of Investigative Medicine</i> , 2006, 54, 412-424.	1.6	66
47	Quantification of Urinary Albumin by Using Protein Cleavage and LC-MS/MS. <i>Clinical Chemistry</i> , 2009, 55, 1100-1107.	3.2	66
48	Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. <i>Kidney International</i> , 2015, 87, 623-631.	5.2	63
49	Pathophysiology and Treatment of Enteric Hyperoxaluria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 487-495.	4.5	63
50	Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. <i>Kidney International</i> , 2013, 84, 818-825.	5.2	62
51	<i>Rhus verniciflua</i> Stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice. <i>Phytomedicine</i> , 2009, 16, 188-197.	5.3	61
52	Cardiac Abnormalities in Primary Hyperoxaluria. <i>Circulation Journal</i> , 2010, 74, 2403-2409.	1.6	61
53	Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. <i>Critical Care</i> , 2014, 18, R110.	5.8	60
54	Cystatin Câ€“Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. <i>American Journal of Kidney Diseases</i> , 2017, 69, 658-666.	1.9	60

#	ARTICLE	IF	CITATIONS
55	No increase in the incidence of acute kidney injury in a population-based annual temporal trends epidemiology study. <i>Kidney International</i> , 2017, 92, 721-728.	5.2	57
56	The genetics of kidney stone disease and nephrocalcinosis. <i>Nature Reviews Nephrology</i> , 2022, 18, 224-240.	9.6	57
57	Effect of Age on the Clinical Presentation of Incident Symptomatic Urolithiasis in the General Population. <i>Journal of Urology</i> , 2013, 189, 158-164.	0.4	56
58	State of the Art for Measurement of Urine Albumin: Comparison of Routine Measurement Procedures to Isotope Dilution Tandem Mass Spectrometry. <i>Clinical Chemistry</i> , 2014, 60, 471-480.	3.2	55
59	Specific renal parenchymal-derived urinary extracellular vesicles identify age-associated structural changes in living donor kidneys. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 29642.	12.2	55
60	Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. <i>Kidney International</i> , 2005, 68, 1784-1792.	5.2	54
61	Nephrolithiasis After Bariatric Surgery for Obesity. <i>Seminars in Nephrology</i> , 2008, 28, 163-173.	1.6	54
62	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. <i>Kidney International Reports</i> , 2021, 6, 1022-1031.	0.8	54
63	Complete Remission in the Nephrotic Syndrome Study Network. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 81-89.	4.5	53
64	Discordance Between Iothalamate and Iohexol Urinary Clearances. <i>American Journal of Kidney Diseases</i> , 2016, 67, 49-55.	1.9	52
65	Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells in culture. <i>Kidney International</i> , 1998, 54, 796-803.	5.2	51
66	Shock Wave Lithotripsy is Not Predictive of Hypertension Among Community Stone Formers at Long-Term Followup. <i>Journal of Urology</i> , 2011, 185, 164-169.	0.4	51
67	The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. <i>Kidney International</i> , 2016, 90, 1080-1089.	5.2	51
68	End Points for Clinical Trials in Primary Hyperoxaluria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1056-1065.	4.5	51
69	Whole Urinary Proteins Coat Calcium Oxalate Monohydrate Crystals to Greatly Decrease Their Adhesion to Renal Cells. <i>Journal of Urology</i> , 2003, 170, 221-225.	0.4	50
70	Geobiology reveals how human kidney stones dissolve in vivo. <i>Scientific Reports</i> , 2018, 8, 13731.	3.3	50
71	Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation. <i>Clinical Chemistry</i> , 2022, 68, 534-539.	3.2	49
72	Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1025-1036.	4.5	48

#	ARTICLE	IF	CITATIONS
73	Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. <i>Kidney International</i> , 2001, 60, 1784-1791.	5.2	47
74	A Liquid Chromatography-Mass Spectrometry Method for the Quantification of Urinary Albumin using a Novel ¹⁵ N-Isotopically Labeled Albumin Internal Standard. <i>Clinical Chemistry</i> , 2007, 53, 540-542.	3.2	47
75	Glomerular Pathology in Dent Disease and Its Association with Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2168-2176.	4.5	47
76	A Target Antigen-Based Approach to the Classification of Membranous Nephropathy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 577-591.	3.0	45
77	Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. <i>ELife</i> , 2020, 9, .	6.0	45
78	Performance of Cystatin C and Creatinine-Based Estimated Glomerular Filtration Rate Equations Depends on Patient Characteristics. <i>Clinical Chemistry</i> , 2015, 61, 1265-1272.	3.2	44
79	Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. <i>Clinical Biochemistry</i> , 2017, 50, 1014-1019.	1.9	44
80	Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium. <i>Molecular Psychiatry</i> , 2019, 24, 1920-1932.	7.9	44
81	Management of Kidney Stones in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1961.	7.4	44
82	EXTRACT FROM HERNIARIA HIRSUTA COATS CALCIUM OXALATE MONOHYDRATE CRYSTALS AND BLOCKS THEIR ADHESION TO RENAL EPITHELIAL CELLS. <i>Journal of Urology</i> , 2004, 172, 1510-1514.	0.4	42
83	Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review. <i>Mayo Clinic Proceedings</i> , 2019, 94, 500-514.	3.0	42
84	Quantification of Asymptomatic Kidney Stone Burden by Computed Tomography for Predicting Future Symptomatic Stone Events. <i>Urology</i> , 2015, 85, 45-50.	1.0	41
85	Probiotics for prevention of urinary stones. <i>Annals of Translational Medicine</i> , 2017, 5, 29-29.	1.7	41
86	Search for Microbial Signatures within Human and Microbial Calcifications Using Soft X-Ray Spectromicroscopy. <i>Journal of Investigative Medicine</i> , 2006, 54, 367-379.	1.6	40
87	Sensitive Spectrophotometric Assay for Plasma Oxalate. <i>Clinical Chemistry</i> , 2005, 51, 2377-2380.	3.2	39
88	Glomerular Volume and Glomerulosclerosis at Different Depths within the Human Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1471-1480.	6.1	39
89	1,2,3,4,6-Penta-O-galloyl-beta-D-glucose reduces renal crystallization and oxidative stress in a hyperoxaluric rat model. <i>Kidney International</i> , 2011, 79, 538-545.	5.2	37
90	Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. <i>Biology of Sex Differences</i> , 2015, 6, 2.	4.1	37

#	ARTICLE	IF	CITATIONS
91	Distinguishing Characteristics of Idiopathic Calcium Oxalate Kidney Stone Formers with Low Amounts of Randall's Plaque. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1757-1763.	4.5	36
92	Gastric Bypass Surgery and Measured and Estimated GFR in Women. <i>American Journal of Kidney Diseases</i> , 2014, 64, 663-665.	1.9	35
93	Modulation of Proliferating Renal Epithelial Cell Affinity for Calcium Oxalate Monohydrate Crystals. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 3052-3062.	6.1	33
94	Performance of flow cytometry to screen urine for bacteria and white blood cells prior to urine culture. <i>Clinical Biochemistry</i> , 2013, 46, 810-813.	1.9	33
95	A reference system for urinary albumin: current status. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 981-9.	2.3	33
96	Creatinine-Based and Cystatin C-Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1640-1649.	4.5	33
97	Clinical and Pathology Findings Associate Consistently with Larger Glomerular Volume. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1960-1969.	6.1	33
98	Altered Calcium and Vitamin D Homeostasis in First-Time Calcium Kidney Stone-Formers. <i>PLoS ONE</i> , 2015, 10, e0137350.	2.5	31
99	Heritability of Urinary Traits That Contribute to Nephrolithiasis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 943-950.	4.5	30
100	Cystatin C Predicts Renal Recovery Earlier Than Creatinine Among Patients With Acute Kidney Injury. <i>Kidney International Reports</i> , 2018, 3, 337-342.	0.8	30
101	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2642-2652.	6.1	30
102	Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. <i>Genetics in Medicine</i> , 2022, 24, 654-662.	2.4	30
103	Controlled Metabolic Diet Reduces Calcium Oxalate Supersaturation but Not Oxalate Excretion After Bariatric Surgery. <i>Urology</i> , 2012, 80, 250-254.	1.0	29
104	Analytical performance of an immunoassay to measure proenkephalin. <i>Clinical Biochemistry</i> , 2018, 58, 72-77.	1.9	28
105	Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F1062-F1076.	2.7	28
106	Understanding, justifying, and optimizing radiation exposure for CT imaging in nephrourology. <i>Nature Reviews Urology</i> , 2019, 16, 231-244.	3.8	28
107	Use of Sevelamer Hydrochloride as an Oxalate Binder. <i>Journal of Urology</i> , 2008, 179, 1407-1410.	0.4	27
108	Human kidney stones: a natural record of universal biomineralization. <i>Nature Reviews Urology</i> , 2021, 18, 404-432.	3.8	27

#	ARTICLE	IF	CITATIONS
109	Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: Proof of principle. <i>International Journal of Nanomedicine</i> , 2008, 3, 243.	6.7	26
110	Importance of Cystatin C Assay Standardization. <i>Clinical Chemistry</i> , 2011, 57, 1209-1211.	3.2	26
111	Serum levels of DNAJB9 are elevated in fibrillaryÂglomerulonephritis patients. <i>Kidney International</i> , 2019, 95, 1269-1272.	5.2	26
112	Tubular secretion of creatinine and kidney function: an observational study. <i>BMC Nephrology</i> , 2020, 21, 108.	1.8	26
113	Analytic and clinical validation of a standardized cystatin C particle enhanced turbidimetric assay (PETIA) to estimate glomerular filtration rate. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1591-6.	2.3	24
114	Challenges in Measuring Glomerular Filtration Rate: A Clinical Laboratory Perspective. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 84-92.	1.4	24
115	Iothalamate Quantification by Tandem Mass Spectrometry to Measure Glomerular Filtration Rate. <i>Clinical Chemistry</i> , 2010, 56, 568-574.	3.2	23
116	Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1397-1403.	0.7	23
117	Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 869-875.	0.7	23
118	Proteomic evaluation of biological nanoparticles isolated from human kidney stones and calcified arteries. <i>Acta Biomaterialia</i> , 2010, 6, 4065-4072.	8.3	22
119	Oxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria. <i>American Journal of Nephrology</i> , 2014, 39, 376-382.	3.1	22
120	Secondarily Infected Nonstruvite Urolithiasis: A Prospective Evaluation. <i>Urology</i> , 2014, 84, 1295-1300.	1.0	21
121	Calcifying nanoparticles promote mineralization in vascular smooth muscle cells: implications for atherosclerosis. <i>International Journal of Nanomedicine</i> , 2014, 9, 2689.	6.7	21
122	Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. <i>American Journal of Kidney Diseases</i> , 2023, 81, 145-155.e1.	1.9	21
123	The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions. <i>Urological Research</i> , 2004, 32, 117-123.	1.5	20
124	Dent disease: A window into calcium and phosphate transport. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7132-7142.	3.6	20
125	Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) AGXT Gene Mutation. <i>Kidney International Reports</i> , 2020, 5, 955-958.	0.8	20
126	Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3608.	4.1	20

#	ARTICLE	IF	CITATIONS
127	Renal cell adaptation to oxalate. <i>Urological Research</i> , 2005, 33, 340-348.	1.5	19
128	Key influence of sex on urine volume and osmolality. <i>Biology of Sex Differences</i> , 2016, 7, 12.	4.1	19
129	GeoBioMed sheds new light on human kidney stone crystallization and dissolution. <i>Nature Reviews Urology</i> , 2020, 17, 1-2.	3.8	19
130	Measurement of urinary TGF- β 21 in patients with diabetes mellitus and normal controls. <i>Clinical Biochemistry</i> , 2013, 46, 1430-1435.	1.9	18
131	Endoscopic and Histologic Findings in a Cohort of Uric Acid and Calcium Oxalate Stone Formers. <i>Urology</i> , 2015, 85, 771-776.	1.0	18
132	Kidney Function After the First Kidney Stone Event. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1744-1752.	3.0	18
133	The Synthesized Plant Metabolite 3,4,5-Tri-O-Galloylquinic Acid Methyl Ester Inhibits Calcium Oxalate Crystal Growth in a <i>Drosophila</i> Model, Downregulates Renal Cell Surface Annexin A1 Expression, and Decreases Crystal Adhesion to Cells. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1609-1621.	6.4	18
134	Characterization of biofilm formed by human-derived nanoparticles. <i>Nanomedicine</i> , 2009, 4, 931-941.	3.3	17
135	Systemic injection of planktonic forms of mammalian-derived nanoparticles alters arterial response to injury in rabbits. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 296, H1434-H1441.	3.2	17
136	1,2,3,4,6-penta-O-galloyl-beta-d-glucose attenuates renal cell migration, hyaluronan expression, and crystal adhesion. <i>European Journal of Pharmacology</i> , 2009, 606, 32-37.	3.5	17
137	Effect of Demographics on Excretion of Key Urinary Factors Related to Kidney Stone Risk. <i>Urology</i> , 2015, 86, 690-696.	1.0	17
138	Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations. <i>Journal of Urology</i> , 2016, 195, 1476-1481.	0.4	17
139	Key role of alkaline phosphatase in the development of human-derived nanoparticles in vitro. <i>Acta Biomaterialia</i> , 2011, 7, 1339-1345.	8.3	16
140	Urinary extracellular vesicle-associated MCP-1 and NGAL derived from specific nephron segments differ between calcium oxalate stone formers and controls. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F1475-F1482.	2.7	16
141	Plasma oxalate: comparison of methodologies. <i>Urolithiasis</i> , 2020, 48, 473-480.	2.0	16
142	SLC2A9 Genotype Is Associated with SLC2A9 Gene Expression and Urinary Uric Acid Concentration. <i>PLoS ONE</i> , 2015, 10, e0128593.	2.5	16
143	Cystone $\text{\textcircled{R}}$ for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers. <i>Urological Research</i> , 2011, 39, 197-203.	1.5	15
144	New Insights Regarding the Interrelationship of Obesity, Diet, Physical Activity, and Kidney Stones. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 211-212.	6.1	15

#	ARTICLE	IF	CITATIONS
145	Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 319.	2.7	15
146	Risk of Symptomatic Kidney Stones During and After Pregnancy. <i>American Journal of Kidney Diseases</i> , 2021, 78, 409-417.	1.9	15
147	Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. <i>Kidney International Reports</i> , 2021, 6, 2862-2884.	0.8	15
148	Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1. <i>Kidney International Reports</i> , 2022, 7, 494-506.	0.8	15
149	Thiazide Diuretic Prophylaxis for Kidney Stones and the Risk of Diabetes Mellitus. <i>Journal of Urology</i> , 2014, 192, 1700-1704.	0.4	14
150	Strategy and rationale for urine collection protocols employed in the NEPTUNE study. <i>BMC Nephrology</i> , 2015, 16, 190.	1.8	14
151	Association between kidney intracapsular pressure and ultrasound elastography. <i>Critical Care</i> , 2017, 21, 251.	5.8	14
152	Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. <i>PLoS ONE</i> , 2017, 12, e0186769.	2.5	14
153	Comparison of high glomerular filtration rate thresholds for identifying hyperfiltration. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1017-1026.	0.7	14
154	Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. <i>Pediatric Nephrology</i> , 2020, 35, 633-640.	1.7	14
155	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 597-606.	2.9	14
156	Establishing a nephrology genetic clinic. <i>Kidney International</i> , 2021, 100, 254-259.	5.2	14
157	In Vivo Entombment of Bacteria and Fungi during Calcium Oxalate, Brushite, and Struvite Urolithiasis. <i>Kidney360</i> , 2021, 2, 298-311.	2.1	14
158	Sulfate but Not Thiosulfate Reduces Calculated and Measured Urinary Ionized Calcium and Supersaturation: Implications for the Treatment of Calcium Renal Stones. <i>PLoS ONE</i> , 2014, 9, e103602.	2.5	13
159	Functional and transport analyses of <i>CLCN5</i> genetic changes identified in Dent disease patients. <i>Physiological Reports</i> , 2016, 4, e12776.	1.7	13
160	Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. <i>Journal of Nephrology</i> , 2016, 29, 45-51.	2.0	13
161	Standardization of Urine Albumin Measurements: Status and Performance Goals. <i>Journal of Applied Laboratory Medicine</i> , 2017, 2, 423-429.	1.3	13
162	Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. <i>Kidney International</i> , 2020, 97, 786-792.	5.2	13

#	ARTICLE	IF	CITATIONS
163	Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity. <i>Kidney International Reports</i> , 2020, 5, 2021-2031.	0.8	13
164	Excretion of urine extracellular vesicles bearing markers of activated immune cells and calcium/phosphorus physiology differ between calcium kidney stone formers and non-stone formers. <i>BMC Nephrology</i> , 2021, 22, 204.	1.8	13
165	Genomics Integration Into Nephrology Practice. <i>Kidney Medicine</i> , 2021, 3, 785-798.	2.0	13
166	Pilot study of reloxalase in patients with severe enteric hyperoxaluria and hyperoxalemia. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 945-948.	0.7	13
167	Aqueous extract of <i>Costus arabicus</i> inhibits calcium oxalate crystal growth and adhesion to renal epithelial cells. <i>Urolithiasis</i> , 2015, 43, 119-124.	2.0	12
168	Longitudinal characterization of renal proximal tubular markers in normotensive and preeclamptic pregnancies. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 312, R773-R778.	1.8	12
169	Impact of Serum Cystatin C-Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients. <i>Pharmacotherapy</i> , 2018, 38, 1068-1073.	2.6	12
170	Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient. <i>American Journal of Kidney Diseases</i> , 2019, 74, 417-420.	1.9	12
171	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	6.2	12
172	Risk Factors for Acute Kidney Injury in Hospitalized Non-Critically Ill Patients: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2020, 95, 459-467.	3.0	12
173	Can biologic nanoparticles initiate nephrolithiasis?. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 308-309.	2.0	11
174	The Influence of Processing and Storage Conditions on Renal Protein Biomarkers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1726-1728.	4.5	11
175	Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases. <i>American Journal of Kidney Diseases</i> , 2021, 77, 816-819.	1.9	11
176	Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1. <i>American Journal of Nephrology</i> , 2016, 43, 454-459.	3.1	10
177	Heritable traits that contribute to nephrolithiasis. <i>Urolithiasis</i> , 2019, 47, 5-10.	2.0	10
178	Patterns of Cystatin C Uptake and Use Across and Within Hospitals. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1649-1659.	3.0	10
179	Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report. <i>American Journal of Kidney Diseases</i> , 2022, 79, 125-128.	1.9	10
180	Primary hyperoxaluria type 1: novel therapies at a glance. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, i17-i22.	2.9	10

#	ARTICLE	IF	CITATIONS
181	Endoscopic and Pathologic Characterization of Papillary Architecture in Struvite Stone Formers. <i>Urology</i> , 2016, 90, 39-44.	1.0	9
182	Overestimation of Glomerular Filtration Rate Among Critically Ill Adults With Hospital-Acquired Oligoanuric Acute Kidney Injury. <i>Journal of Pharmacy Practice</i> , 2016, 29, 125-131.	1.0	9
183	Treatment of Cholesterol Embolization Syndrome in the Setting of an Acute Indication for Anticoagulation Therapy. <i>Journal of Medical Cases</i> , 2014, 5, 376-379.	0.7	9
184	Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C. <i>Diagnostics</i> , 2021, 11, 2291.	2.6	9
185	Looking for a Better Creatinine. <i>Clinical Chemistry</i> , 2014, 60, 1036-1039.	3.2	8
186	Digenic mutations of human OCRL paralogs in Dent's disease type 2 associated with Chiari I malformation. <i>Human Genome Variation</i> , 2016, 3, 16042.	0.7	8
187	Polymorphisms in Renal Ammonia Metabolism Genes Correlate With 24-Hour Urine pH. <i>Kidney International Reports</i> , 2017, 2, 1111-1121.	0.8	8
188	Cl ⁻ and H ⁺ coupling properties and subcellular localizations of wildtype and disease-associated variants of the voltage-gated Cl ⁻ /H ⁺ exchanger CLC-5. <i>Journal of Biological Chemistry</i> , 2020, 295, 1464-1473.	3.4	8
189	High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. <i>Kidney International Reports</i> , 2021, 6, 1895-1903.	0.8	8
190	Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2208-2215.	0.7	8
191	Genotype Phenotype Correlation in Dent Disease 2 and Review of the Literature: OCRL Gene Pleiotropism or Extreme Phenotypic Variability of Lowe Syndrome?. <i>Genes</i> , 2021, 12, 1597.	2.4	8
192	Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. <i>Kidney Medicine</i> , 2022, 4, 100419.	2.0	8
193	Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria. , 2022, 1, .		8
194	Genetic Causes of Kidney Stones and Kidney Failure. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2012, 10, 2-18.	0.8	7
195	Association of urinary citrate excretion, pH, and net gastrointestinal alkali absorption with diet, diuretic use, and blood glucose concentration. <i>Physiological Reports</i> , 2017, 5, e13411.	1.7	7
196	Antiolithic activity and biotransformation of galloylquinic acids by <i>Aspergillus alliaceus</i> ATCC10060, <i>Aspergillus brasiliensis</i> ATCC 16404, and <i>Cunninghamella elegans</i> ATCC 10028b. <i>Biocatalysis and Agricultural Biotechnology</i> , 2019, 18, 101012.	3.1	7
197	Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors. <i>American Journal of Nephrology</i> , 2022, 53, 273-281.	3.1	7
198	The association of matrix Gla protein isomers with calcification in capsules surrounding silicone breast implants. <i>Biomaterials</i> , 2011, 32, 8364-8373.	11.4	6

#	ARTICLE	IF	CITATIONS
199	Characterization of Inner Medullary Collecting Duct Plug Formation Among Idiopathic Calcium Oxalate Stone Formers. <i>Urology</i> , 2016, 94, 47-52.	1.0	6
200	Non-steroidal anti-inflammatory drugs for renal colic. <i>Lancet, The</i> , 2016, 387, 1971-1972.	13.7	6
201	Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 448-460.	2.4	6
202	Automatic detection of calcium phosphate deposit plugs at the terminal ends of kidney tubules. <i>Healthcare Technology Letters</i> , 2019, 6, 271-274.	3.3	6
203	Automated radiomic analysis of CT images to predict likelihood of spontaneous passage of symptomatic renal stones. <i>Emergency Radiology</i> , 2021, 28, 781-788.	1.8	6
204	Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis. <i>Frontiers in Medicine</i> , 2021, 8, 592357.	2.6	6
205	Sex Steroid Hormone Levels May Not Explain Gender Differences in Development of Nephrolithiasis. <i>Journal of Endourology</i> , 2015, 29, 1341-1345.	2.1	5
206	Fecal electrolyte testing for evaluation of unexplained diarrhea: Validation of body fluid test accuracy in the absence of a reference method. <i>Clinical Biochemistry</i> , 2015, 48, 1126-1130.	1.9	5
207	Bariatric Surgery and Kidney Health. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1085-1086.	6.1	5
208	Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	5
209	Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic. <i>PLoS ONE</i> , 2020, 15, e0243618.	2.5	5
210	Uncovering a Novel Stone in 27 Patients: Calcium Tartrate Tetrahydrate. <i>Urology</i> , 2019, 126, 49-53.	1.0	4
211	Genome-Wide Association Meta-Analysis of Individuals of European Ancestry Identifies Suggestive Loci for Sodium Intake, Potassium Intake, and Their Ratio Measured from 24-Hour or Half-Day Urine Samples. <i>Journal of Nutrition</i> , 2020, 150, 2635-2645.	2.9	4
212	Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria. <i>BMC Nephrology</i> , 2020, 21, 133.	1.8	4
213	Invited response to recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. <i>American Journal of Transplantation</i> , 2018, 18, 527.	4.7	4
214	Clinical Outcomes and Histological Patterns in Oxalate Nephropathy due to Enteric and Nonenteric Risk Factors. <i>American Journal of Nephrology</i> , 2021, 52, 961-968.	3.1	4
215	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. <i>Pediatric Nephrology</i> , 2021, 36, 2747-2757.	1.7	3
216	Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 414-422.	4.5	3

#	ARTICLE	IF	CITATIONS
217	A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate. <i>Kidney International Reports</i> , 2022, 7, 1690-1693.	0.8	3
218	Inching toward a Greater Understanding of Genetic Hypercalciuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1460-1462.	4.5	2
219	Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function. <i>American Journal of Transplantation</i> , 2021, , .	4.7	2
220	1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. <i>Analytical Chemistry</i> , 2021, 93, 13177-13186.	6.5	2
221	Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1. <i>American Journal of Kidney Diseases</i> , 2022, 80, 373-382.	1.9	2
222	Medical Management. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2004, 2, 237-252.	0.8	1
223	Isolation, Propagation, and Analysis of Biological Nanoparticles. <i>Methods in Molecular Biology</i> , 2011, 790, 263-275.	0.9	1
224	Infection-Related Kidney Stones. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2011, 9, 218-228.	0.8	1
225	Eosinophiluria is common among patients after ileal conduit surgery. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1869-71.	2.3	1
226	Diagnostic Imaging for Kidney Stones—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1465.	7.4	1
227	CYP24A1 deficiency causing persistent hypercalciuria in a stone former. <i>Journal of Nephrology</i> , 2021, 34, 949-951.	2.0	1
228	Surgical interventions for symptomatic urinary stones during pregnancy. <i>Chinese Medical Journal</i> , 2021, 134, 1994-1996.	2.3	1
229	Microsporidium Infection—Associated Acute Kidney Injury in a Patient With HIV. <i>Kidney Medicine</i> , 2021, 4, 100390.	2.0	1
230	Commentary. <i>Clinical Chemistry</i> , 2013, 59, 890-890.	3.2	0
231	Commentary. <i>Clinical Chemistry</i> , 2016, 62, 440-440.	3.2	0
232	Editorial Comment. <i>Journal of Urology</i> , 2016, 196, 1147-1148.	0.4	0
233	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 409-410.	0.4	0
234	The first Sri Lankan family with Dent disease-1 due to a pathogenic variant in the CLCN5 gene: a case report. <i>BMC Research Notes</i> , 2017, 10, 539.	1.4	0

#	ARTICLE	IF	CITATIONS
235	The Case An unusual cause of tender skin lesion in an end-stage kidney disease patient. <i>Kidney International</i> , 2021, 99, 275-276.	5.2	0
236	Has Noninvasive Kidney Transplant Surveillance Finally Arrived?. <i>Clinical Chemistry</i> , 2021, 67, 1047-1049.	3.2	0
237	MO047 STABLE EGFR IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 TREATED WITH LUMASIRAN, REGARDLESS OF KIDNEY FUNCTION AT START OF TREATMENT. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
238	FC 013 LUMASIRAN DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
239	End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease. <i>American Journal of Kidney Diseases</i> , 2021, , .	1.9	0
240	Spectromicroscopy of microbial signatures within human calcifications. <i>FASEB Journal</i> , 2006, 20, A101.	0.5	0
241	Biofilm formation by biologic nanoparticles may require extracellular RNA and intact ribosomal function. <i>FASEB Journal</i> , 2009, 23, 817.8.	0.5	0
242	Biologic Nanoparticles Calcify and Form Bacteria-like Biofilm In Vitro. <i>FASEB Journal</i> , 2009, 23, 593.14.	0.5	0
243	Comparison of clinical features of pregnant and non-pregnant females with primary hyperoxaluria. <i>Journal of Nephrology</i> , 2022, , 1.	2.0	0
244	New Insights Regarding Organ Transplantation in Primary Hyperoxaluria Type 1. <i>Kidney International Reports</i> , 2022, 7, 146-148.	0.8	0
245	FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0